礼来口服GLP-1药物Orforglipron在两个成功的三期试验中展现出优越的血糖控制,重新确认其作为2型糖尿病基础治疗的潜力。
礼来口服GLP-1药物Orforglipron在两个成功的三期试验中展现出优越的血糖控制,重新确认其作为2型糖尿病基础治疗的潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.